Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Zachary joined the Bing Center in 2003 as clinical research coordinator and was so taken with medical research and the study of WM that despite his background in Mathematics and Physics, he retrained in Biology and ultimately received Ph.D. in Pathology from Boston University in 2015. He is now Instructor of Medicine at Harvard Medical School and the Bliss Family Investigator at the Bing Center for WM where he oversees the genomic and bioinformatic efforts for the group. With over 125 peer reviewed articles, his achievements include the initial identification and characterization of the recurrent MYD88, CXCR4, and ARID1A mutations in WM. He also published the initial genomic and transcriptional characterization of both MYD88 mutated and MYD88 wildtype WM. He contributed to the efforts characterizing primary and acquired resistance to BTK inhibitor therapy, WM clonal evolution, and familial Waldenstrom’s Macroglobulinemia. He has given over 60 scientific talks including at the American Society of Hematology, The American Society of Clinical Oncology, International Conference on Malignant Lymphoma, and the International Workshops on both Waldenstrom’s and Multiple Myeloma. He is very committed to patient education and has spoken in over 30 patient educational events. Dr. Hunter is the recipient of the Robert A. Kyle award and the American Society of Hematology Scholar Award. His current research includes the use of large multi-omic datasets and artificial intelligence models to characterize the evolution and distinct subtypes of WM, alternative splicing and RNA regulation, and WM Familial predisposition.